December 4, 2018 / 6:31 AM / 10 days ago

BRIEF-Innate Pharma Announces Updated Results On IPH4102

Dec 4 (Reuters) - INNATE PHARMA:

* ANNOUNCED ON MONDAY UPDATED RESULTS THAT SUPPORT ADVANCEMENT OF IPH4102 IN REFRACTORY SÉZARY SYNDROME

* DIFFERENTIATING PROFILE OF IPH4102 CONFIRMED: HIGH AND DURABLE RESPONSE, FAVORABLE SAFETY PROFILE WITH LONG-TERM FOLLOW-UP AND SUBSTANTIAL IMPROVEMENT IN QUALITY OF LIFE

* EXPECTS TO INITIATE A GLOBAL PHASE II STUDY (“TELLOMAK”) IN DIFFERENT SUBTYPES OF T-CELL LYMPHOMAS IN THE FIRST HALF OF 2019

Source text for Eikon:

Further company coverage: (Gdynia Newsroom)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below